Adeel Khan, MD, MPH, MS

In the final cross Q&A session from the multiple myeloma module, panelists discuss implications of IKEMA and consider the importance of biochemical versus clinical progression.

Expert Wilson Gonsalves, MD, shares clinical data in multiple myeloma centered on the distinction between biochemical versus clinical progression.

Following a review of data with low-dose dasatinib in chronic myeloid leukemia, key opinion leaders from the Mayo Clinic and UT Southwestern consider its role in real-world practice.

In the last presentation of the session, Abhishek Mangaonkar, MBBS, details clinical trial data with low-dose dasatinib in patients with chronic myeloid leukemia.

Covering the first of two abstracts, Wilson Gonsalves, MD, reviews data from the IKEMA study of isatuximab KD in patients with relapsed/refractory multiple myeloma.

In this cross Q&A, both the Mayo Clinic and UT Southwestern teams share insight on the role of olverembatinib in relapsed/refractory chronic myeloid leukemia.

Panelists from both the Mayo Clinic and UT Southwestern comment on data from ALLIANCE A061202 and consider the role of isatuximab in patients with relapsed/refractory multiple myeloma.

A comprehensive review of chronic myeloid leukemia olverembatinib data led by expert Kebede Begna, MD, from the Mayo Clinic team.

Adeel Khan, MD, MPH, MS, expert in multiple myeloma management, reviews data from the ALLIANCE A061202 trial of isatuximab + pomalidomide + dexamethasone in relapsed/refractory disease.

Experts from the Mayo Clinic and UT Southwestern share insight on the CARTITUDE-4 study and ciltacabtagene autoleucel in the second cross Q&A session.

Following a review of the retrospective analysis of PACE, experts reflect on its importance in understanding the risk of arterial occlusive events with ponatinib.

Key opinion leader Prashant Kapoor, MD, FACP, shares data from the CARTITUDE-4 study of ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma.

A focused discussion led by expert Abhishek Mangaonkar, MBBS, on a retrospective analysis elucidating arterial occlusive events within the PACE study.

Panelists follow up with questions and comments on the KarMMa-3 study in relapsed/refractory multiple myeloma and consider how idecabtagene vicleucel might fit into real-world practice.

Expert perspectives from the Mayo Clinic and UT Southwestern teams on applications of the OPTIC study and optimal ponatinib dosing in chronic myeloid leukemia.

Key opinion leader Kebede Begna, MD, reviews data from the OPTIC study focused on ponatinib dosing in chronic-phase CML.

Expert Larry Anderson, Jr, MD, PhD, FACP, reviews data from the KarMMa-3 study of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma.

Expert panelists from UT Southwestern and the Mayo Clinic introduce themselves and prepare for a team-vs-team debate surrounding recent clinical trial data in chronic myeloid leukemia.

Expert panelists from UT Southwestern and the Mayo Clinic introduce themselves and prepare for a team-vs-team debate surrounding recent clinical trial data in relapsed/refractory multiple myeloma.